Study of Genome-associated Mechanisms of Diabetic Nephropathy and Evaluation of Nephroprotective Therapy in Patients With Type 2 Diabetes Mellitus in the Kazakh Population
Launched by ASTANA MEDICAL UNIVERSITY · Jun 17, 2025
Trial Information
Current as of July 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
To achieve the goal of the project, the following tasks were formulated, consisting of a subset of direct sequences designed to consistently lead to results. The study of genome-associated mechanisms of diabetic nephropathy and the evaluation of the effectiveness of nephroprotective therapy in patients with type 2 diabetes mellitus in the Kazakh population may provide new diagnostic opportunities and influence treatment options for patients, and this hypothesis has been tested on five proposed tasks:
1. Recruiting research participants.
* Make a list of potential participants
* Invi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • consent of the participant (signing the informed consent form);
- • patients with a verified diagnosis of type 2 diabetes mellitus of Kazakh nationality
- • age from 18 years to 65 years
- Exclusion Criteria:
- • өage under 18 and over 65 years
- • undiagnosed type 2 diabetes mellitus
- • lack of informed consent
- • pregnancy and lactation at the time of inclusion in the study;
- • oncological disease at the time of inclusion in the study, decompensated concomitant somatic pathology.
About Astana Medical University
Astana Medical University is a leading educational and research institution in Kazakhstan, dedicated to advancing medical knowledge and enhancing healthcare through innovative research and clinical trials. With a commitment to excellence in medical education, the university fosters collaboration among healthcare professionals, researchers, and industry partners to address pressing health challenges. By sponsoring clinical trials, Astana Medical University aims to contribute to the development of effective therapies and improve patient outcomes, while ensuring adherence to the highest ethical standards and regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Astana, , Kazakhstan
Patients applied
Trial Officials
Murzakhmetova Aigerim Orazbayevna Murzakhmetova Aigerim Orazbayevna, PhD
Study Director
Astana Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported